BARDA and Dascena, Inc. partner to further advance machine learning software to predict early health deterioration in hospitalized COVID-19 patients

About Image

BARDA is partnering with Dascena, Inc. to expand the use of the company's algorithm-based software to empower clinicians to predict disease severity in COVID-19 patients.

This partnership will leverage Dascena’s experience in developing improved prediction tools to advance the development of their COViage™ system, which received the U.S. Food and Drug Administration’s Emergency Use Authorization (EUA) to predict unstable blood pressure as well as respiratory failure, which requires ventilation in COVID-19 patients. Further clinical and user evaluation of the tool in additional hospitals will aid Dascena in expanding its use and availability across the country.

Hospitalized COVID-19 patients are at heightened risk of rapid health deterioration and severe outcomes. However, few scoring systems are available to help healthcare professionals predict COVID-19 patient prognosis. Dascena’s next-generation precision medicine approach analyzes data from the patient’s electronic health record to provide healthcare professionals with timely warning of COVID-19 patients at heightened risk of experiencing unstable blood pressure or respiratory failure. The advance notice would give healthcare professionals an important additional tool to guide interventional decision making, such as mechanical ventilation.

Under this partnership, Dascena will advance the development of COViage through clinical validation of the technology to support a request for FDA 510(k) clearance of COViage and to conduct user assessments to aid in further expansion and implementation of the system at additional clinical sites. Dascena will complete a randomized controlled trial to prospectively assess the ability of the algorithm to predict respiratory decline. Dascena will further engage clinical care teams to assess utility of the COViage system and to demonstrate readiness for large-scale deployment.

This award is one component of BARDA’s COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.

About Dascena:

The following information is provided by company and does not indicate endorsement by the federal government of the company or its products.

Dascena is developing machine learning diagnostic algorithms to enable early disease intervention and improve care outcomes for patients. Our COViage algorithm, which has an Emergency Use Designation by the FDA, is intended to predict hemodynamic instability and respiratory decompensation in individuals who are hospitalized with severe COVID-19. COViage is intended to serve as clinical decision support for healthcare professionals while they navigate the clinical and logistical challenges resulting from the COVID-19 pandemic. For more information, visit

Last Updated: June 09, 2021

COVID-19 Medical Countermeasure Portfolio

This award is one component of BARDA's expanding COVID-19 medical countermeasure portfolio; visit BARDA's COVID-19 Portfolio to learn more.